Respiratory Pathogen Articles & Analysis
6 news found
Funding from the BARDA Division of Research, Innovation, and Ventures (DRIVe) enabled the company to reformulate LMN-301, previously developed for oral delivery, and to evaluate its potential as an anti-viral therapeutic delivered to the respiratory tract, the primary site of SARS-CoV-2 infection. The efficacy of the intranasal formulation was evaluated by collaborators at the ...
Pravibismane exhibits broad-spectrum, potent in vitro activity against chronic respiratory infection and chronic wound relevant pathogens and their biofilms including NTM, multidrug resistant P. aeruginosa and MRSA. ...
The new Vitassay SARS-CoV-2 + Flu A + B + RSV + Adeno Resp. is a rapid, immunochromatographic assay for the simultaneous qualitative detection of nucleoprotein antigen of SARS-CoV-2, Influenza type A, Influenza type B, RSV and Adenovirus from nasopharyngeal swabs samples from patients suspected of COVID-19 infection and/or Influenza A and/or Influenza B and/or Respiratory ...
We are pleased to share the news that Fusion Genomics has received a $1 million award to conduct a study evaluating our comprehensive, novel ONETest PathoGenome assay for the detection of pathogens associated with respiratory tract infections (RTIs). Due in great part to limitations associated with current diagnostic tests, RTIs are a leading cause of morbidity, ...
Respiratory infections affect everyone, and they can be caused by a large number of pathogens. During respiratory season, a targeted flu test risks missing the real cause of illness. ...
Investigators have narrowed down his current whereabouts to a tropical climate with no extradition treaty. Respiratory Syncytial Virus RSV was once told to pick on somebody his own size—that’s how he got his start infecting infants. He’s little, he’s fierce, and he’s everywhere, which is why fellow Paramyxoviridae gang members call him the ...